New Risk • May 17
New major risk - Revenue and earnings growth Earnings have declined by 2.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.3% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Anuncio • Mar 31
Dexxos Participações S.A., Annual General Meeting, Apr 29, 2026 Dexxos Participações S.A., Annual General Meeting, Apr 29, 2026. Location: hotel windsor guanabara. av. presidente vargas 392, 4 andar, sala guanabara iii, centro, city and state of rio de janeiro., rio de janeiro. Brazil Reported Earnings • Mar 27
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: R$1.33. Revenue: R$2.14b (up 18% from FY 2024). Net income: R$143.7m (flat on FY 2024). Profit margin: 6.7% (down from 8.0% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Revenue is forecast to grow 2.1% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Chemicals industry in South America. New Risk • Mar 26
New major risk - Revenue and earnings growth Earnings have declined by 0.05% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.05% per year over the past 5 years. Minor Risk Dividend is not well covered by cash flows (284% cash payout ratio). Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Frederico Atila Neves was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Major Estimate Revision • Nov 21
Consensus EPS estimates increase by 17%, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from R$2.22b to R$2.08b. EPS estimate rose from R$1.24 to R$1.45. Net income forecast to grow 5.2% next year vs 31% growth forecast for Chemicals industry in Brazil. Consensus price target of R$12.00 unchanged from last update. Share price rose 2.9% to R$8.20 over the past week. Reported Earnings • Nov 17
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: R$516.7m (up 4.6% from 3Q 2024). Net income: R$29.5m (down 23% from 3Q 2024). Profit margin: 5.7% (down from 7.8% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 5% per year. Buy Or Sell Opportunity • Nov 06
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.6% to R$7.88. The fair value is estimated to be R$9.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 6.6% in 2 years. Earnings are forecast to decline by 3.8% in the next 2 years. Major Estimate Revision • Sep 16
Consensus EPS estimates fall by 14%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from R$2.08b to R$2.22b. EPS estimate fell from R$1.45 to R$1.24 per share. Net income forecast to shrink 13% next year vs 33% growth forecast for Chemicals industry in Brazil . Consensus price target of R$12.00 unchanged from last update. Share price was steady at R$8.44 over the past week. Buy Or Sell Opportunity • Aug 29
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to R$8.34. The fair value is estimated to be R$10.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 0.4% in 2 years. Earnings are forecast to grow by 4.1% in the next 2 years. Reported Earnings • Aug 13
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: R$597.3m (up 36% from 2Q 2024). Net income: R$38.9m (up 29% from 2Q 2024). Profit margin: 6.5% (down from 6.9% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in South America. Buy Or Sell Opportunity • Aug 12
Now 21% undervalued Over the last 90 days, the stock has risen 9.0% to R$8.44. The fair value is estimated to be R$10.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.6% over the last 3 years. Earnings per share has declined by 5.3%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 8.4% in the next 2 years. Buy Or Sell Opportunity • Jul 18
Now 21% undervalued Over the last 90 days, the stock has risen 11% to R$8.67. The fair value is estimated to be R$10.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.6% over the last 3 years. Earnings per share has declined by 5.3%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 8.4% in the next 2 years. Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to R$9.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Chemicals industry globally. Total returns to shareholders of 17% over the past three years. Reported Earnings • May 17
First quarter 2025 earnings released First quarter 2025 results: Revenue: R$603.2m (up 56% from 1Q 2024). Net income: R$52.6m (up 30% from 1Q 2024). Profit margin: 8.7% (down from 10% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in South America. Anuncio • Mar 27
Dexxos Participações S.A., Annual General Meeting, Apr 28, 2025 Dexxos Participações S.A., Annual General Meeting, Apr 28, 2025. Location: hotel windsor guanabara. av. presidente vargas 392, 3 andar, sala pancetti, centro, rio de janeiro. Brazil Reported Earnings • Mar 26
Full year 2024 earnings: Revenues exceed analyst expectations Full year 2024 results: Revenue: R$1.81b (up 3.7% from FY 2023). Net income: R$144.2m (down 20% from FY 2023). Profit margin: 8.0% (down from 10% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 3% per year. New Risk • Mar 17
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 6.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (16% increase in shares outstanding). Reported Earnings • Nov 13
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: R$494.1m (up 20% from 3Q 2023). Net income: R$38.5m (down 3.6% from 3Q 2023). Profit margin: 7.8% (down from 9.7% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 3% per year. New Risk • Aug 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (16% increase in shares outstanding). Reported Earnings • Aug 11
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: R$438.9m (flat on 2Q 2023). Net income: R$30.1m (down 26% from 2Q 2023). Profit margin: 6.9% (down from 9.2% in 2Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Global Chemicals industry. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year. Reported Earnings • May 12
First quarter 2024 earnings released First quarter 2024 results: Revenue: R$387.9m (down 17% from 1Q 2023). Net income: R$40.4m (down 11% from 1Q 2023). Profit margin: 10% (in line with 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.8% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 5% per year. Reported Earnings • Mar 26
Full year 2023 earnings released Full year 2023 results: Revenue: R$1.75b (down 17% from FY 2022). Net income: R$180.8m (up 21% from FY 2022). Profit margin: 10% (up from 7.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in South America. Anuncio • Aug 18
Dexxos Participações S.A. to Report Q3, 2023 Results on Nov 09, 2023 Dexxos Participações S.A. announced that they will report Q3, 2023 results on Nov 09, 2023 Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to R$11.05, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry globally. Total returns to shareholders of 254% over the past three years. Reported Earnings • Aug 11
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: R$442.7m (down 20% from 2Q 2022). Net income: R$40.8m (up 36% from 2Q 2022). Profit margin: 9.2% (up from 5.4% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 1.6% growth forecast for the Chemicals industry in South America. Reported Earnings • May 14
First quarter 2023 earnings released First quarter 2023 results: Revenue: R$469.1m (down 24% from 1Q 2022). Net income: R$45.6m (down 22% from 1Q 2022). Profit margin: 9.7% (in line with 1Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to R$9.40, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 13x in the Chemicals industry globally. Total returns to shareholders of 588% over the past three years. Reported Earnings • Mar 30
Full year 2022 earnings: Revenues miss analyst expectations Full year 2022 results: Revenue: R$2.10b (up 18% from FY 2021). Net income: R$149.9m (down 22% from FY 2021). Profit margin: 7.1% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 7.0%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Amin Murad is the most experienced director on the board, commencing their role in 2019. Independent Director Fernando Furtado was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment deteriorated over the past week After last week's 15% share price decline to R$7.71, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 7x in the Chemicals industry in South America. Total returns to shareholders of 284% over the past three years. Valuation Update With 7 Day Price Move • Oct 07
Investor sentiment improved over the past week After last week's 18% share price gain to R$7.00, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 5x in the Chemicals industry in South America. Total returns to shareholders of 311% over the past three years. Reported Earnings • Aug 13
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: R$556.1m (up 33% from 2Q 2021). Net income: R$30.0m (down 55% from 2Q 2021). Profit margin: 5.4% (down from 16% in 2Q 2021). Over the next year, revenue is forecast to grow 7.4% compared to a 2.7% decline forecast for the industry in Brazil. Over the last 3 years on average, earnings per share has increased by 71% per year whereas the company’s share price has increased by 69% per year. Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment deteriorated over the past week After last week's 16% share price decline to R$7.77, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Chemicals industry globally. Total returns to shareholders of 1,061% over the past three years. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improved over the past week After last week's 16% share price gain to R$8.82, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry globally. Total returns to shareholders of 1,060% over the past three years. Board Change • Apr 27
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Amin Murad is the most experienced director on the board, commencing their role in 2019. Independent Director Fernando Furtado was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 19% share price gain to R$10.41, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 5x in the Chemicals industry in Brazil. Total returns to shareholders of 1,328% over the past three years. Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment deteriorated over the past week After last week's 15% share price decline to R$8.82, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 6x in the Chemicals industry in Brazil. Total returns to shareholders of 1,326% over the past three years. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improved over the past week After last week's 22% share price gain to R$9.80, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 6x in the Chemicals industry in Brazil. Total returns to shareholders of 1,577% over the past three years. Reported Earnings • Nov 12
Third quarter 2021 earnings released: EPS R$0.73 (vs R$0.23 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: R$453.6m (up 57% from 3Q 2020). Net income: R$68.1m (up 213% from 3Q 2020). Profit margin: 15% (up from 7.6% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 134% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 18% share price gain to R$10.01, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 8x in the Chemicals industry in Brazil. Total returns to shareholders of 1,227% over the past three years. Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment deteriorated over the past week After last week's 15% share price decline to R$9.89, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 8x in the Chemicals industry in Brazil. Total returns to shareholders of 1,190% over the past three years. Reported Earnings • Aug 14
Second quarter 2021 earnings released: EPS R$0.71 (vs R$0.68 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: R$417.5m (up 111% from 2Q 2020). Net income: R$66.5m (up 4.1% from 2Q 2020). Profit margin: 16% (down from 32% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 167% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improved over the past week After last week's 15% share price gain to R$47.90, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 12x in the Chemicals industry in South America. Total returns to shareholders of 2,228% over the past three years. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment deteriorated over the past week After last week's 16% share price decline to R$43.73, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 11x in the Chemicals industry in South America. Total returns to shareholders of 1,701% over the past three years. Reported Earnings • Jun 06
First quarter 2021 earnings released: EPS R$1.29 (vs R$0.37 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: R$345.4m (up 50% from 1Q 2020). Net income: R$40.4m (up 250% from 1Q 2020). Profit margin: 12% (up from 5.0% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 189% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 24% share price gain to R$46.49, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 12x in the Chemicals industry in South America. Total returns to shareholders of 2,022% over the past three years. Reported Earnings • May 21
First quarter 2021 earnings released: EPS R$1.30 (vs R$0.37 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: R$345.4m (up 50% from 1Q 2020). Net income: R$40.4m (up 250% from 1Q 2020). Profit margin: 12% (up from 5.0% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 145% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 04
Investor sentiment improved over the past week After last week's 18% share price gain to R$35.40, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 14x in the Chemicals industry in South America. Total returns to shareholders of 1,291% over the past three years. Upcoming Dividend • Apr 25
Upcoming dividend of R$0.84 per share Eligible shareholders must have bought the stock before 29 April 2021. Payment date: 31 December 2021. Trailing yield: 2.7%. Lower than top quartile of Brazilian dividend payers (4.9%). Lower than average of industry peers (3.9%). Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment improved over the past week After last week's 15% share price gain to R$24.30, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 14x in the Chemicals industry in South America. Total returns to shareholders of 875% over the past three years. Reported Earnings • Mar 23
Full year 2020 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: R$994.7m (up 25% from FY 2019). Net income: R$119.2m (up 378% from FY 2019). Profit margin: 12% (up from 3.1% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 112% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment improved over the past week After last week's 23% share price gain to R$24.57, the stock trades at a trailing P/E ratio of 7.8x, up from the previous P/E ratio of 6.4x. Average P/E is 13x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 814%. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment deteriorated over the past week After last week's 16% share price decline to R$20.10, the stock is trading at a trailing P/E ratio of 6.4x, down from the previous P/E ratio of 7.6x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 634%. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment improved over the past week After last week's 17% share price gain to R$25.85, the stock is trading at a trailing P/E ratio of 13.2x, up from the previous P/E ratio of 11.3x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 774%. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 20% share price gain to R$22.70, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 11x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 659%. Is New 90 Day High Low • Dec 29
New 90-day high: R$22.70 The company is up 18% from its price of R$19.26 on 30 September 2020. The Brazilian market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 61% over the same period. Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment improved over the past week After last week's 16% share price gain to R$20.45, the stock is trading at a trailing P/E ratio of 10.4x, up from the previous P/E ratio of 9x. This compares to an average P/E of 10x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 584%. Valuation Update With 7 Day Price Move • Nov 19
Market pulls back on stock over the past week After last week's 21% share price decline to R$17.00, the stock is trading at a trailing P/E ratio of 8.7x, down from the previous P/E ratio of 11x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 574%. Reported Earnings • Oct 22
Third quarter earnings released Over the last 12 months the company has reported total profits of R$98.2m, up 234% from the prior year. Total revenue was R$915.1m over the last 12 months, up 15% from the prior year. Valuation Update With 7 Day Price Move • Oct 17
Market bids up stock over the past week After last week's 15% share price gain to R$19.75, the stock is trading at a trailing P/E ratio of 7.1x, up from the previous P/E ratio of 6.1x. This compares to an average P/E of 9x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 719%. Is New 90 Day High Low • Sep 19
New 90-day high: R$21.67 The company is up 233% from its price of R$6.50 on 19 June 2020. The Brazilian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 26% over the same period.